Matches in Wikidata for { <http://www.wikidata.org/entity/Q57173042> ?p ?o ?g. }
- Q57173042 description "article scientifique publié en 2018" @default.
- Q57173042 description "article" @default.
- Q57173042 description "artículu científicu" @default.
- Q57173042 description "im August 2018 veröffentlicher wissenschaftlicher Artikel" @default.
- Q57173042 description "wetenschappelijk artikel" @default.
- Q57173042 description "наукова стаття, опублікована в серпні 2018" @default.
- Q57173042 name "Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised" @default.
- Q57173042 name "Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised" @default.
- Q57173042 type Item @default.
- Q57173042 label "Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised" @default.
- Q57173042 label "Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised" @default.
- Q57173042 prefLabel "Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised" @default.
- Q57173042 prefLabel "Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised" @default.
- Q57173042 P1433 Q57173042-906C552E-97F1-4EB1-B239-9ABA11E28EC8 @default.
- Q57173042 P1476 Q57173042-AFEBE16F-B866-446A-AF69-CDA22A92EF4F @default.
- Q57173042 P2093 Q57173042-0091DD9F-9232-4A05-AA4E-F7ADA6FDF076 @default.
- Q57173042 P2093 Q57173042-0B1A251D-ECA1-4792-9C3E-F348754E16DB @default.
- Q57173042 P2093 Q57173042-0D85811E-891B-4D2F-AA5F-C6E3C9558FB1 @default.
- Q57173042 P2093 Q57173042-18EE54DA-A4D6-4103-ADFD-39990A77D996 @default.
- Q57173042 P2093 Q57173042-1F6F7F27-AC13-4715-A010-2C8641A5A35F @default.
- Q57173042 P2093 Q57173042-52E9225D-778E-4761-B078-CA66F000EE10 @default.
- Q57173042 P2093 Q57173042-5425753A-AD09-4BF0-9BAE-DE9126919048 @default.
- Q57173042 P2093 Q57173042-544EAACF-EC01-4F6E-8C0C-09C887D4ECD1 @default.
- Q57173042 P2093 Q57173042-6B45B885-83C2-489A-B2BB-58E3E143089F @default.
- Q57173042 P2093 Q57173042-76C394C9-2495-4655-A99E-389112D08E39 @default.
- Q57173042 P2093 Q57173042-85529837-58B4-44AE-B77E-966B8A105B01 @default.
- Q57173042 P2093 Q57173042-86D86FE3-2563-4DD0-BAFC-CA3791A30DCD @default.
- Q57173042 P2093 Q57173042-8CFB67B3-53E4-4579-8C4B-6DF91E2762B1 @default.
- Q57173042 P2093 Q57173042-8FAB4D8B-C8AC-453A-8558-422B9B753346 @default.
- Q57173042 P2093 Q57173042-9FACB758-AAFF-4003-B51F-CD347023CFE3 @default.
- Q57173042 P2093 Q57173042-A18AE873-C630-4C55-B678-0BAD236528CC @default.
- Q57173042 P2093 Q57173042-CC4D17E3-3D72-4292-8802-3F6503736803 @default.
- Q57173042 P2093 Q57173042-D129D62A-F8EF-4C28-BE00-2801C13F75EE @default.
- Q57173042 P2093 Q57173042-E8327C55-7094-4E34-8140-15ADC4918759 @default.
- Q57173042 P2093 Q57173042-E922EF08-9CEF-4414-8727-2FE7E4F6F335 @default.
- Q57173042 P2860 Q57173042-0996446D-41A2-44A7-9F4E-5A54ED2D83A5 @default.
- Q57173042 P2860 Q57173042-22162795-AD25-4C70-8986-D3BFC0E4C071 @default.
- Q57173042 P2860 Q57173042-41213EC3-1EC9-47C9-9C20-DD946D3D3475 @default.
- Q57173042 P2860 Q57173042-56545CFF-12D4-4476-8F4D-BD24C0A05FBE @default.
- Q57173042 P2860 Q57173042-57EEDEF3-CD1E-4791-9B74-22C865346E3F @default.
- Q57173042 P2860 Q57173042-5B028005-3025-4266-8BDD-F6EEEA4CFCB4 @default.
- Q57173042 P2860 Q57173042-5E54B8F6-67B8-4870-AB96-2E55CA200782 @default.
- Q57173042 P2860 Q57173042-6223FFB1-45E2-4514-A2FA-5955ACB7D93E @default.
- Q57173042 P2860 Q57173042-72DA2D5A-4156-4B34-83A1-80383D5D4D2A @default.
- Q57173042 P2860 Q57173042-7927BECD-AAA6-4B64-ADD0-9669F7B8A6FE @default.
- Q57173042 P2860 Q57173042-931E1186-9C3E-4592-B7E0-24B42DCCFE07 @default.
- Q57173042 P2860 Q57173042-A2B8AF66-8F13-4C9B-AB8A-215B4CFEF7A5 @default.
- Q57173042 P2860 Q57173042-ADAF2B20-0814-48ED-9CA4-2E1178E17B67 @default.
- Q57173042 P2860 Q57173042-C214BF8F-6AD7-4857-AB08-FFC00EB9E938 @default.
- Q57173042 P2860 Q57173042-D471D3FB-1765-4645-89AF-DE49F5C8038D @default.
- Q57173042 P2860 Q57173042-E8A62443-E0EF-4B04-B5DA-F695441C88E7 @default.
- Q57173042 P2860 Q57173042-EFC01928-8E7F-41E9-B8AC-44554F49FF5A @default.
- Q57173042 P2860 Q57173042-F87A0D17-D158-4B6B-BDE7-0FD374467824 @default.
- Q57173042 P2860 Q57173042-FA793C83-DBD2-4B44-8308-407AEF242550 @default.
- Q57173042 P304 Q57173042-484AD1FC-BAE4-4AB3-B063-6940AA2806DF @default.
- Q57173042 P31 Q57173042-E90C8291-1CFC-4553-BE17-A759ECBEFC8F @default.
- Q57173042 P356 Q57173042-BD9B054C-2268-49B2-B4DB-5C23CD274550 @default.
- Q57173042 P407 Q57173042-67FFFC47-1595-4DF5-A843-519179E7930D @default.
- Q57173042 P433 Q57173042-05F42755-4BFB-4269-972C-F541A9EB5B87 @default.
- Q57173042 P478 Q57173042-48558E36-6946-40BC-BFE2-B9D977529B6B @default.
- Q57173042 P50 Q57173042-6B51A825-BFB2-4A0B-8888-8455E7198251 @default.
- Q57173042 P50 Q57173042-FEBC94F8-8FB2-4463-9F4C-15AF227D7F08 @default.
- Q57173042 P577 Q57173042-99303B4A-4733-4E7F-A260-700C49AAE43E @default.
- Q57173042 P698 Q57173042-184F93DF-E203-4F29-868F-FF32C7EDA26C @default.
- Q57173042 P921 Q57173042-0D396F89-E642-444B-A383-02AFB43BB005 @default.
- Q57173042 P921 Q57173042-1EC037C8-1CB5-47D3-90D3-EBAA283BC63A @default.
- Q57173042 P921 Q57173042-296B3AD1-A8DA-4662-A1A2-24A87B5C5F3F @default.
- Q57173042 P921 Q57173042-4956FE89-287B-4693-9D4F-1EF43BC5842A @default.
- Q57173042 P921 Q57173042-4A574030-509D-41FA-A877-615E1EAE9DE9 @default.
- Q57173042 P356 S1470-2045(18)30343-7 @default.
- Q57173042 P698 30026002 @default.
- Q57173042 P1433 Q13747613 @default.
- Q57173042 P1476 "Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial" @default.
- Q57173042 P2093 "Andrew Clamp" @default.
- Q57173042 P2093 "Clare Scott" @default.
- Q57173042 P2093 "Daniel Eek" @default.
- Q57173042 P2093 "David Espinoza" @default.
- Q57173042 P2093 "Diane Provencher" @default.
- Q57173042 P2093 "Emma Gibbs" @default.
- Q57173042 P2093 "Eric Pujade-Lauraine" @default.
- Q57173042 P2093 "Florence Joly" @default.
- Q57173042 P2093 "Jacob Korach" @default.
- Q57173042 P2093 "Kenji Tamura" @default.
- Q57173042 P2093 "Lari B Wenzel" @default.
- Q57173042 P2093 "Laura Vidal" @default.
- Q57173042 P2093 "Lucy Davies" @default.
- Q57173042 P2093 "Manuel Rodrigues" @default.
- Q57173042 P2093 "Maria Ornella Nicoletto" @default.
- Q57173042 P2093 "Michael Friedlander" @default.
- Q57173042 P2093 "Ralph Bloomfield" @default.
- Q57173042 P2093 "Richard T Penson" @default.
- Q57173042 P2093 "Val Gebski" @default.
- Q57173042 P2093 "Vanda Salutari" @default.
- Q57173042 P2860 Q27336251 @default.
- Q57173042 P2860 Q28131668 @default.
- Q57173042 P2860 Q33417673 @default.
- Q57173042 P2860 Q34422265 @default.
- Q57173042 P2860 Q35705716 @default.
- Q57173042 P2860 Q36433053 @default.
- Q57173042 P2860 Q37201213 @default.